News

Pierre Gholam, MD, discusses the phase 3 LEAP-002 study of lenvatinib and pembrolizumab for unresectable hepatocellular carcinoma.

Investigators of the phase 2 KRYSTAL-1 have reported important findings that may be practice-changing for oncologists who treat various KRAS G12C-mutant solid tumors, in the future.

An analysis of 4 deidentified data sets revealed that HRAS mutations occurred in 3% to 4% of patients with head and neck squamous cell carcinoma.

Researchers are backing further investigation of 60 mg selinexor plus ruxolitinib based on positive phase 1/2 findings presented at the AACR Annual Meeting 2023.

The new Prescription Drug User Fee Act action date for quizartinib for use in patients with newly diagnosed FLT3-ITD-positive acute myeloid leukemia has been set to July 24, 2023.

Findings presented at the ASCO April Plenary Series showed that there was a significant event-free survival improvement among patients treated with toripalimab in the phase 3 Neotorch study.

Chad Tang, MD, discusses currently available treatment options and recent research in the prostate cancer space.

The phase 3 CheckMate 914 study has missed its primary end point, and the lack of efficacy of nivolumab plus ipilimumab over placebo in the study has led investigators to refer oncologists back to the standard of care, pembrolizumab, as seen in KEYNOTE-564.

Researchers are working to optimize the outcomes associated with CAR T-cell therapy, focusing on unique combinations that may enhance T-cell fitness, improving tumor eradication and treatment outcomes.

In an interview, Samer A. Srour, MD, MS, reviewed data from the dose-expansion phase of an ongoing phase 1 trial of Orca-Q in the haploidentical stem cell transplant setting for patients with high-risk hematologic malignancies.

In an interview with Targeted Oncology, Mitchell E. Horwitz, MD, discussed the FDA approval of omidubicel for the treatment of patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant.

On the heels of a positive ODAC vote, polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone is now FDA-approved.

Complete remission was achieved in 99% patients with refractory leukemia or hematologic relapse when treated with CD19- and CD22-chimeric antigen receptor T-cell therapy in a phase 2 trial.

DKN-01, an anti-DKK1 antibody, is being evaluated with bevacizumab and chemotherapy for patients with advanced colorectal cancer in the phase 2 DeFianCe trial.

Melanie Goldfarb, MD, MSc, FACS, FACE, discusses the current treatment landscape for patients with thyroid cancer.

At the 2023 National Comprehensive Cancer Network Annual Conference, Arlene O. Siefker-Radtke, MD, gave an assessment on where emerging targeted therapies for patients with metastatic or advanced bladder stand.

News results from. the phase 3 AEGEAN trial further support the use of PD-1/PD-L1 inhibitors in the neoadjuvant and adjuvant setting for patients with non–small cell lung cancer.

Whole-exome sequencing demonstrated the ability to identify genetic conditions in patients for whom clinical guidelines did not require testing.

In an interview, Ashish Saxena, MD, discussed the benefit of radiation for the treatment of small cell lung cancer, combining radiation with immune checkpoint blockade treatments, and the next steps for the space.

Neeta Somaiah, MD, discusses the expanding role of targeted therapies in patients with gastrointestinal stromal tumor and how these treatments are bolstering later lines of therapy.

A trial of TOS-358, a first-in-class covalent PI3Kα inhibitor, for various solid tumors dosed its first patient.

An artificial intelligence model has been shown to predict the risk of low and high distant recurrence in patients with endometrial cancer.

John P. Diaz, MD, provides an overview of the topics to be discusses during the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.

At the AACR 2023 Annual Meeting, a presentation revealed that people with colorectal cancer and African ancestry are less likely to be candidates for targeted therapy.

Studies have increasingly supported the use of total neoadjuvant therapy, moving chemotherapy use ahead of surgical resection of rectal tumors.

The combination of botensilimab and balstilimab is moving down the FDA pipeline and may become an approved treatment for non-microsatellite instability-high and deficient mismatch repair metastatic colorectal cancer in the future.

Hatem Soliman, MD, explains how to test for HER2 status in patients with breast cancer.

The FDA plans to conduct a speedy review of an approval application for trifluridine plus tipiracil and bevacizumab for the treatment of metastatic colorectal cancer.

The success of BRAF/MEK combinations has led to the discovery of safety and preliminary activity with an investigational pan-RAF/MEK combination.

Data presented at the 2023 AACR Annual Meeting on treatment with BGB-3245 in advanced or refractory tumors with a mutation in the MAPK pathway support ongoing investigations of BGB-3245 in defined cohorts during the dose-expansion portion of a phase 1a/1b trial.